grade III meningioma

Summary

grade III meningioma (MONDO:0020634) is a disease and 8 clinical trials. Top therapeutic interventions include bevacizumab and lutetium oxodotreotide lu-177. A subtype of meningioma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 8

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	grade III meningioma
Mondo ID	MONDO:0020634
NCIT	C38938
UMLS	C0280801
MedGen	79186
GARD	0025190
Is cancer (heuristic)	no

Also known as: grade 3 meningioma · grade III meningioma · meningioma, malignant · WHO grade III meningioma

Disease family

This is a subtype of meningioma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › central nervous system disorder › central nervous system neoplasm › tumor of meninges › meningioma › grade III meningioma

Related subtypes (36): intraspinal meningioma, intraventricular meningioma, intraorbital meningioma, clear cell meningioma, posterior cranial fossa meningioma, anterior cranial fossa meningioma, skull base meningioma, benign meningioma, secretory meningioma, lymphoplasmacyte-rich meningioma, pediatric meningioma, microcystic meningioma, middle cranial fossa meningioma, rhabdoid meningioma, optic nerve sheath meningioma, lung meningioma, malignant leptomeningeal tumor, jugular foramen meningioma, angiomatous meningioma, psammomatous meningioma, fibrous meningioma, meningothelial meningioma, transitional meningioma, petrous apex meningioma, gasserian ganglion meningioma, skin meningioma, periocular meningioma, pineal region meningioma, parapharyngeal meningioma, radiation-induced meningioma, familial meningioma, papillary meningioma, optic tract meningioma, grade II meningioma, intracranial meningioma, supratentorial meningioma

Subtypes (1): anaplastic meningioma

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 8.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	3
Not specified	3
PHASE1/PHASE2	1
PHASE1	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT02847559	PHASE2	RECRUITING	Optune Delivered Electric Field Therapy and Bevacizumab in Treating Patients With Recurrent or Progressive Grade 2 or 3 Meningioma
NCT03604978	PHASE1/PHASE2	ACTIVE_NOT_RECRUITING	Nivolumab and Multi-fraction Stereotactic Radiosurgery With or Without Ipilimumab in Treating Patients With Recurrent Grade II-III Meningioma
NCT04082520	PHASE2	RECRUITING	Lutathera for the Treatment of Inoperable, Progressive Meningioma After External Beam Radiation Therapy
NCT06275919	PHASE2	RECRUITING	Regorafenib for Recurrent Meningioma (MIRAGE Trial)
NCT01082926	PHASE1	COMPLETED	Phase I Study of Cellular Immunotherapy for Recurrent/Refractory Malignant Glioma Using Intratumoral Infusions of GRm13Z40-2, An Allogeneic CD8+ Cytolitic T-Cell Line Genetically Modified to Express the IL 13-Zetakine and HyTK and to be Resistant to Glucocorticoids, in Combination With Interleukin-2
NCT04278118	Not specified	RECRUITING	Hypofractionated Proton Therapy for Benign Intracranial Brain Tumors, the HiPPI Study
NCT06557512	Not specified	RECRUITING	Adjuvant Hypofractionated Stereotactic Radiosurgery for Intermediate-risk Meningioma
NCT04728568	Not specified	UNKNOWN	Exploratory Study of PD-1 Neoadjuvant Treatment of Recurrent Meningioma

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
BEVACIZUMAB	4	1
LUTETIUM OXODOTREOTIDE LU-177	4	1